Santen Pharmaceutical Co., Ltd.
4536.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥494 | ¥521 | ¥438 | ¥491 |
| - Cash | ¥93 | ¥95 | ¥58 | ¥83 |
| + Debt | ¥34 | ¥35 | ¥36 | ¥33 |
| Enterprise Value | ¥436 | ¥462 | ¥416 | ¥440 |
| Revenue | ¥300 | ¥302 | ¥279 | ¥266 |
| % Growth | -0.6% | 8.2% | 4.8% | – |
| Gross Profit | ¥171 | ¥179 | ¥166 | ¥157 |
| % Margin | 57% | 59.2% | 59.5% | 58.8% |
| EBITDA | ¥69 | ¥56 | ¥14 | ¥55 |
| % Margin | 22.9% | 18.7% | 5.1% | 20.5% |
| Net Income | ¥36 | ¥27 | -¥15 | ¥27 |
| % Margin | 12.1% | 8.8% | -5.4% | 10.2% |
| EPS Diluted | 103.68 | 72.37 | -38.6 | 67.97 |
| % Growth | 43.3% | 287.5% | -156.8% | – |
| Operating Cash Flow | ¥61 | ¥73 | ¥37 | ¥46 |
| Capital Expenditures | -¥7 | -¥11 | -¥25 | -¥36 |
| Free Cash Flow | ¥54 | ¥62 | ¥13 | ¥10 |